%0 Journal Article
%A Schmitz, Sebastian B M
%A Gülden, Jakob
%A Niederreiter, Marlene
%A Eichner, Cassandra
%A Werner, Jens
%A Mayer, Barbara
%T Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor Pimitespib.
%J Cells
%V 14
%N 11
%@ 2073-4409
%C Basel
%I MDPI
%M DKFZ-2025-01203
%P 836
%D 2025
%X The prognosis of advanced (UICC IIb-IV) primary colorectal cancer (pCRC) remains poor. More effective targeted therapies are needed. Heat shock protein 90 alpha/beta (Hsp90α/β) expression was immunohistologically quantified in 89 pCRCs and multivariately correlated with survival. Pimitespib (Pim, TAS-116), a Hsp90α/β-specific inhibitor, was tested in pCRC cell lines and patient-derived cancer spheroids (PDCS) and referenced to the pan-Hsp90 inhibitor ganetespib (Gan, STA-9090) and standard-of-care therapies. A total of 26.97
%K Humans
%K HSP90 Heat-Shock Proteins: metabolism
%K HSP90 Heat-Shock Proteins: antagonists & inhibitors
%K Colorectal Neoplasms: drug therapy
%K Colorectal Neoplasms: metabolism
%K Colorectal Neoplasms: pathology
%K Female
%K Male
%K Aged
%K Middle Aged
%K Cell Line, Tumor
%K Prognosis
%K Triazoles: pharmacology
%K Triazoles: therapeutic use
%K Spheroids, Cellular: drug effects
%K Spheroids, Cellular: metabolism
%K CRC (Other)
%K Hsp90α/β (Other)
%K TAS-116 (Other)
%K chemosensitization (Other)
%K ganetespib (Other)
%K patient stratification (Other)
%K patient-derived cancer spheroid model (Other)
%K personalized therapy (Other)
%K pimitespib (Other)
%K prognosis (Other)
%K HSP90 Heat-Shock Proteins (NLM Chemicals)
%K STA 9090 (NLM Chemicals)
%K Triazoles (NLM Chemicals)
%K HSP90AB1 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40498011
%2 pmc:PMC12154481
%R 10.3390/cells14110836
%U https://inrepo02.dkfz.de/record/302004